We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
First published during the 2019 to 2022 Johnson Conservative government
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
This consultation (ARM88) welcomes views on proposals to classify Nexium Control 20mg Gastro-Resistant Tablets as a general sales list (GSL) product in the UK.
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 6 December 2021
Find alerts and recalls issued by MHRA
You must tell DVLA if you have hypoglycaemia - download the correct form to let them know
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).